ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,948.87
1.37%
Dow Jones
42,762.98
0.87%
US Dollar vs MXN
20.66775
0.29%
Brent Oil
76.435
0.76%
Bitcoin
98,768.71
1.93%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Spyre Therapeutics Inc (SYRE)

  7. Spyre Therapeutics Inc (SYRE) Noticias

SYRE

Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SYRE
FechaHoraFuenteTítuloSímboloCompañía
18/12/202407:00PR Newswire (US)Spyre Therapeutics Added to the Nasdaq Biotechnology IndexNASDAQ:SYRESpyre Therapeutics Inc
02/12/202416:03PR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
02/12/202407:00PR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A AntibodiesNASDAQ:SYRESpyre Therapeutics Inc
25/11/202416:11PR Newswire (US)Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:SYRESpyre Therapeutics Inc
19/11/202416:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
19/11/202415:38Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRESpyre Therapeutics Inc
18/11/202420:18PR Newswire (US)Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common StockNASDAQ:SYRESpyre Therapeutics Inc
18/11/202415:14PR Newswire (US)Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded WarrantsNASDAQ:SYRESpyre Therapeutics Inc
18/11/202415:09Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
18/11/202415:03Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
14/11/202416:50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
12/11/202406:30PR Newswire (US)Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the PotentialNASDAQ:SYRESpyre Therapeutics Inc
11/11/202415:05PR Newswire (US)Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024NASDAQ:SYRESpyre Therapeutics Inc
08/11/202415:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
07/11/202415:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRESpyre Therapeutics Inc
07/11/202415:05PR Newswire (US)Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
07/11/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRESpyre Therapeutics Inc
30/10/202415:05PR Newswire (US)Spyre Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:SYRESpyre Therapeutics Inc
25/10/202415:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRESpyre Therapeutics Inc
23/10/202413:10Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SYRESpyre Therapeutics Inc
14/10/202407:00PR Newswire (US)Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and CombinationsNASDAQ:SYRESpyre Therapeutics Inc
02/10/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SYRESpyre Therapeutics Inc
01/10/202417:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
01/10/202407:00PR Newswire (US)Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical OfficerNASDAQ:SYRESpyre Therapeutics Inc
20/09/202415:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SYRESpyre Therapeutics Inc
10/09/202415:47PR Newswire (US)Spyre Therapeutics to Participate in Upcoming Investor ConferenceNASDAQ:SYRESpyre Therapeutics Inc
07/08/202415:05PR Newswire (US)Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
18/07/202407:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
18/06/202406:30PR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel DiseaseNASDAQ:SYRESpyre Therapeutics Inc
29/05/202407:30PR Newswire (US)Spyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SYRESpyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SYRE

Su Consulta Reciente

BIT
NUS
Nusco
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados